#United States #Los Angeles #Schall Law Firm #Securities Fraud #Ultragenyx

Opportunity for Investors in Ultragenyx Pharmaceutical, Inc.

The Schall Law Firm has recently issued a reminder for investors in Ultragenyx Pharmaceutical Inc. regarding a significant class action lawsuit that has been initiated against the company for alleged securities fraud. This marks a critical opportunity for affected shareholders to take action and join the endeavor led by the firm.

Background of the Case

Ultragenyx Pharmaceutical, a biotechnology company specializing in rare diseases, has been accused of making false and misleading statements about the efficacy of its treatments. Specifically, these statements have been made during the class period from August 3, 2023, to December 26, 2025. The lawsuit claims that the company violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with SEC Rule 10b-5, which pertains to fraudulent activity in securities trading.

Investors who purchased Ultragenyx securities during this timeframe may find themselves eligible to recover financial losses if they decide to participate in the lawsuit before the deadline.

Details of Allegations

The complaint elaborates on the company's misleading communications to the market regarding its drug candidate aimed at treating Osteogenesis Imperfecta (OI). Investors were led to believe that Ultragenyx had a comprehensive understanding of how its treatment would affect patients. However, this was called into question when results from the Phase III ORBIT study indicated that the expected reduction in the annualized fracture rate was not statistically significant.

The fallout from these disclosures has been severe, leading to significant damage for investors upon realizing that Ultragenyx’s public statements were not only false but also materially deceiving throughout the aforementioned class period. As market reactions unfolded, it became apparent that the company's previous lofty expectations were not based on factual scientific data, and as a result, many shareholders face financial setbacks.

How to Participate

For investors who have suffered losses related to their investments in Ultragenyx Pharmaceutical, joining the class action is a pathway to seek recovery. The Schall Law Firm specializes in shareholder rights and securities class action lawsuits, making them a formidable advocate for investors.

Those interested can reach out to the firm before the looming deadline of April 6, 2026. Brian Schall of the Schall Law Firm can be contacted for a free discussion concerning individual rights and the next steps. His office is located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, with a direct phone line at 310-301-3335.

What’s Next?

While it’s important to note that the class has not yet been certified, those who take action now can ensure they are represented in the case, unlike absent class members who may miss their chance to seek justice for their losses.

If you or someone you know is an investor affected by this situation, this is a crucial time to consider joining the class action. The Schall Law Firm remains committed to representing shareholders like you and potentially recouping the financial losses incurred due to the alleged fraud by Ultragenyx.

For further information and inquiries, you can visit the firm's website at www.schallfirm.com or contact them via email. Don’t miss your chance to take a stand in this significant legal matter that affects the rights of shareholders across the country.